TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.
Shandong Xinhua Pharmaceutical Company Limited announced that its Epinephrine Hydrochloride Injection has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration. This approval marks a significant milestone for the company, enhancing its product credibility and potentially strengthening its market position in the pharmaceutical industry, particularly in the treatment of severe dyspnea, anaphylactic shock, and as a primary rescue drug for cardiopulmonary resuscitation.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the production and distribution of prescription drugs, with a particular emphasis on chemical pharmaceuticals.
Average Trading Volume: 2,163,129
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.72B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.